Document is current
Any future updates will be listed below
-
Authors
Jhaveri, Ravi
Skolnik, Neil
Bandell, Allyn
- License Information
-
More Information
Article History
Received: 21 May 2025
Accepted: 11 November 2025
First Online: 23 November 2025
Competing interests
: R.J. has received consulting fees from MedImmune/AstraZeneca, Sanofi, Gilead, and Seqirus; and funding for investigator-initiated research from GSK. N.S. has acted as advisory board member and consultant for AstraZeneca, Teva, Lilly, Sanofi, Sanofi Pasteur, GSK, Abbo, and Novo Nordisk has been a speaker for AstraZeneca, Lilly, GSK, Teva, and Heartland, and has received research support from AstraZeneca, GSK, Novo Nordisk, and Novartis. A.B. is an employee and shareholder AstraZeneca.
